Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Key Highlights
- ➤Verastem Oncology (VSTM) priced a $250 million stock and pre-funded warrant offering
- ➤30,937,500 shares priced at $8.00 each
- ➤Pre-funded warrants cover 312,503 shares, priced at $7.9999 each
- ➤Proceeds will fund VS-7375 development, working capital, and general corporate purposes
- ➤Offering is expected to close on or about October 15, 2026
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 312,503 shares of its common stock at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.
Get started
Create a free account to read the full story.